CLINICAL_TRIALS
trial_result
· 2011-01-10
Clinical Trial Update: Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Summary
This update reports the completion of a Phase 1 study evaluating the vascular disrupting agent NPI-2358 in patients with advanced solid tumors or lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nereus Pharmaceuticals, Inc. | Conditions: Cancer | Phase 1 | Status: COMPLETED